The Zytoprotec team is delighted that this was possible despite the difficult financing environment for start-ups during the last two years. And we would like to thank all new investors for the trust they have placed in us. The money will primarily be used for further research, possibly for a small Austrian Phase 2b Study to substantiate the recently discovered systemic anti-inflammatory effect of our lead product PDprotec®, and to prepare the Chinese Phase 3 Study, which will be sponsored and conducted by a Joint Venture currently being established with our partner Vantage Group, Shanghai. It is planned to conduct a 2nd closing in March 2024 to give other currently interested investors the opportunity to participate in Zytoprotec.
Contact
Zytoprotect
p: +43-664-3382814
e: b.zinner@zytoprotec.com und office(at)zytoprotec.com